Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 1652 to 1701 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1652\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AARF DOMAIN CONTAINING KINASE 2; PUTATIVE UBIQUINONE BIOSYNTHESIS PROTEIN AARF. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0340138\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.142333\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238973393\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ADCK2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1653\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AARF DOMAIN CONTAINING KINASE 4. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0274831\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.115005\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238973088\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ADCK4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1654\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 13 (26S PROTEASOME REGULATORY SUBUNIT S11) (26S PROTEASOME REGULATORY SUBUNIT P40.5). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.75685\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.16764\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238931823\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMD13\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1655\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
APURINIC/APYRIMIDINIC ENDONUCLEASE 2; APURINIC/APYRIMIDINIC ENDONUCLEASE-LIKE 2; APEX NUCLEASE-LIKE 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0730689\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.305877\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238883277\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
APEX2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1656\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
COPPER-TRANSPORTING ATPASE 1 (EC 3.6.3.4) (COPPER PUMP 1) (MENKES DISEASE-ASSOCIATED PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0806616\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.337708\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238850131\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ATP7A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1657\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CYCLIN M2; ANCIENT CONSERVED DOMAIN PROTEIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.317455\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.3291\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238849597\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CNNM2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1658\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRIPARTITE MOTIF PROTEIN 3 (RING FINGER PROTEIN 22) (BRAIN-EXPRESSED RING FINGER PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.271838\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.13816\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238839882\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TRIM3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1659\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TCD37 HOMOLOG; PRUNE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.118202\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.494902\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238839205\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PRUNE\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1660\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CYCLIN M4; ANCIENT CONSERVED DOMAIN PROTEIN 4. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.285611\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.19583\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238839133\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CNNM4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1661\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
COPPER-TRANSPORTING ATPASE 2 (EC 3.6.3.4) (COPPER PUMP 2) (WILSON DISEASE-ASSOCIATED PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0958705\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.401402\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238839119\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ATP7B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1662\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0879782\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.368359\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238838199\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PRUNE2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1663\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CYCLIN M1; ANCIENT CONSERVED DOMAIN PROTEIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.264548\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.10767\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238832865\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CNNM1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1664\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CYCLIN M3; ANCIENT CONSERVED DOMAIN PROTEIN 3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.258494\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.08234\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238828834\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CNNM3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1665\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"NUCLEAR INHIBITOR OF PROTEIN PHOSPHATASE-1 (NIPP-1) (PROTEIN PHOSPHATASE 1, REGULATORY INHIBITOR SUBUNIT 8) [INCLUDES: ACTIVATOR OF RNA DECAY (EC 3.1.4.-) (ARD-1)]. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.179673\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.752395\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238801427\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PPP1R8\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1666\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
44050 PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.03729\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.156155\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238801191\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C10orf83\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1667\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEASOME SUBUNIT ALPHA TYPE 3 (EC 3.4.25.1) (PROTEASOME COMPONENT C8) (MACROPAIN SUBUNIT C8) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT C8). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.956289\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4.005\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238773783\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMA3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1668\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MESODERM INDUCTION EARLY RESPONSE 1. \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0415385\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.173966\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.238773668\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1669\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
DEPDC5\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1670\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0336981\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.14113\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238773471\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MIER3\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1671\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0335839\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.140652\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238773\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MIER2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1672\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SPLICING FACTOR, PROLINE-AND GLUTAMINE-RICH (POLYPYRIMIDINE TRACT- BINDING PROTEIN-ASSOCIATED SPLICING FACTOR) (PTB-ASSOCIATED SPLICING FACTOR) (PSF) (DNA-BINDING P52/P100 COMPLEX, 100 KDA SUBUNIT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.263446\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.10501\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238410512\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SFPQ\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1673\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.847098\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.55339\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238391508\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
IMP3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1674\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 10 (26S PROTEASOME REGULATORY SUBUNIT P28) (GANKYRIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.41158\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.7269\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238334588\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMD10\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1675\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PARASPECKLE PROTEIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.203402\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.853581\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238292558\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSPC1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1676\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"54 KDA NUCLEAR RNA- AND DNA-BINDING PROTEIN (P54(NRB)) (P54NRB) (55 KDA NUCLEAR PROTEIN) (NMT55) (NON-POU DOMAIN-CONTAINING OCTAMER- BINDING PROTEIN) (DNA-BINDING P52/P100 COMPLEX, 52 KDA SUBUNIT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.201833\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.847008\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238289367\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NONO\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1677\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.461707\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.93809\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238227843\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KCTD17\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1678\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.581959\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.44287\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238227577\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KCTD5\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1679\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.48192\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.02294\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.23822753\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KCTD2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1680\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 12 (26S PROTEASOME REGULATORY SUBUNIT P55). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.563839\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.36701\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238207274\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1681\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DELTA 1-PYRROLINE-5-CARBOXYLATE SYNTHETASE (P5CS) [INCLUDES: GLUTAMATE 5-KINASE (EC 2.7.2.11) (GAMMA-GLUTAMYL KINASE) (GK); GAMMA-GLUTAMYL PHOSPHATE REDUCTASE (GPR) (EC 1.2.1.41) (GLUTAMATE-5-SEMIALDEHYDE DEHYDROGENASE) (GLUTAMYL-GAMMA-SEMIALDEHYDE DEHYDR\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0224883\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0944225\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238166751\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ALDH18A1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1682\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE 3; PYRIDINE NUCLEOTIDE ADENYLYLTRANSFERASE 3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.192536\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.808409\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238166572\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NMNAT3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1683\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUCLEOLAR PROTEIN NOP5 (NUCLEOLAR PROTEIN 5) (NOP58) (HSPC120). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.160247\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.672842\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238164383\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1684\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
60S RIBOSOMAL PROTEIN L37 (G1.16). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0238444\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.100146\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.238096379\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
RPL37\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1685\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SPLICING FACTOR, ARGININE/SERINE-RICH 1 (PRE-MRNA SPLICING FACTOR SF2, P33 SUBUNIT) (ALTERNATIVE SPLICING FACTOR ASF-1). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
SFRS1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1686\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SORTING NEXIN 17. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0476887\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.200292\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.23809588\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SNX17\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1687\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AMIDOPHOSPHORIBOSYLTRANSFERASE PRECURSOR (EC 2.4.2.14) (GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE) (ATASE) (GPAT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.214575\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.901215\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238095238\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PPAT\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1688\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SERINE/THREONINE-PROTEIN KINASE NEK3 (EC 2.7.1.37) (NIMA-RELATED PROTEIN KINASE 3) (HSPK 36). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0267969\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.112547\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238095196\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NEK3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1689\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE, LIVER (EC 1.2.1.12) (GAPDH). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.414602\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.74133\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238095019\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GAPDH\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1690\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SERINE/THREONINE-PROTEIN KINASE NEK1 (EC 2.7.1.37) (NIMA-RELATED PROTEIN KINASE 1) (NY-REN-55 ANTIGEN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.035086\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.147362\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238093946\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NEK1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1691\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PUTATIVE INORGANIC POLYPHOSPHATE/ATP-NAD KINASE (EC 2.7.1.23) (POLY(P)/ATP NAD KINASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.195442\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.821038\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238042575\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NADK\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1692\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"ADP,ATP CARRIER PROTEIN, FIBROBLAST ISOFORM (ADP/ATP TRANSLOCASE 2) (ADENINE NUCLEOTIDE TRANSLOCATOR 2) (ANT 2). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.032514\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.136688\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.237870186\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
SLC25A5\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1693\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"ADP,ATP CARRIER PROTEIN, HEART/SKELETAL MUSCLE ISOFORM T1 (ADP/ATP TRANSLOCASE 1) (ADENINE NUCLEOTIDE TRANSLOCATOR 1) (ANT 1). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
SLC25A4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1694\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DYNACTIN COMPLEX 50 KDA SUBUNIT (50 KDA DYNEIN-ASSOCIATED POLYPEPTIDE) (DYNAMITIN) (DCTN-50) (DYNACTIN 2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.375423\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.57827\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.237869946\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DCTN2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1695\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0256535\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.107847\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.237869389\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SLC25A31\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1696\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"ADP,ATP CARRIER PROTEIN, LIVER ISOFORM T2 (ADP/ATP TRANSLOCASE 3) (ADENINE NUCLEOTIDE TRANSLOCATOR 3) (ANT 3). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0311972\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.131153\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.237868749\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SLC25A6\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1697\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ASPARAGINE SYNTHETASE [GLUTAMINE-HYDROLYZING] (EC 6.3.5.4) (GLUTAMINE- DEPENDENT ASPARAGINE SYNTHETASE) (TS11 CELL CYCLE CONTROL PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0326245\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.137154\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.237867652\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ASNS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1698\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"VACUOLAR ATP SYNTHASE CATALYTIC SUBUNIT A, UBIQUITOUS ISOFORM (EC 3.6.3.14) (V-ATPASE A SUBUNIT 1) (VACUOLAR PROTON PUMP ALPHA SUBUNIT 1) (V-ATPASE 69 KDA SUBUNIT 1) (ISOFORM VA68). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.712561\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.99562\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.23786762\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ATP6V1A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1699\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HCV NS3-TRANSACTIVATED PROTEIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0338955\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.142498\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.237866496\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ASNSD1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1700\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.044904\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.188793\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.237847802\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1701\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NEMO-LIKE KINASE; LIKELY ORTHOLOG OF MOUSE NEMO LIKE KINASE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.210207\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.883788\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.237847764\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NLK\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/